Jun 01, 2017 12:39 pm UTC| Business
BERKELEY, Calif., June 01, 2017 -- Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with three distinct immunotherapy technologies, announced today that the U.S. Food and Drug Administration (FDA) has...
Jun 01, 2017 12:39 pm UTC| Business
BERKELEY, Calif., June 01, 2017 -- Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with three distinct immunotherapy technologies, announced today that the U.S. Food and Drug Administration (FDA) has...
Jun 01, 2017 12:39 pm UTC| Business
BERKELEY, Calif., June 01, 2017 -- Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with three distinct immunotherapy technologies, announced today that the U.S. Food and Drug Administration (FDA) has...
Jun 01, 2017 12:39 pm UTC| Business
BERKELEY, Calif., June 01, 2017 -- Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with three distinct immunotherapy technologies, announced today that the U.S. Food and Drug Administration (FDA) has...
Jun 01, 2017 12:39 pm UTC| Business
BERKELEY, Calif., June 01, 2017 -- Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with three distinct immunotherapy technologies, announced today that the U.S. Food and Drug Administration (FDA) has...
Jun 01, 2017 12:39 pm UTC| Business
BERKELEY, Calif., June 01, 2017 -- Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with three distinct immunotherapy technologies, announced today that the U.S. Food and Drug Administration (FDA) has...
Jun 01, 2017 12:39 pm UTC| Business
BERKELEY, Calif., June 01, 2017 -- Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with three distinct immunotherapy technologies, announced today that the U.S. Food and Drug Administration (FDA) has...